ClearPoint Neuro (NASDAQ:CLPT) Trading Up 5.9% - Still a Buy?

Key Points

• ClearPoint Neuro's stock rose 5.9%, reaching $22.14 during a trading session despite a 60% decline in trading volume compared to its average.
• Analysts have upgraded ClearPoint Neuro's rating, with a consensus of "Buy" and a new price target adjustment from $8.00 to $9.00 by Stifel Nicolaus.
• Recent quarterly earnings showed a revenue of $9.22 million but a loss per share of ($0.21), missing estimates by $0.01, alongside a substantial negative return on equity of 94.44%.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) shares were up 5.9% during trading on Thursday . The company traded as high as $21.60 and last traded at $22.14. Approximately 165,213 shares changed hands during trading, a decline of 60% from the average daily volume of 417,102 shares. The stock had previously closed at $20.91.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on CLPT shares. Stifel Nicolaus increased their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wall Street Zen upgraded ClearPoint Neuro from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $19.67.

ClearPoint Neuro Price Performance

The company has a 50-day moving average of $12.03 and a two-hundred day moving average of $12.27. The stock has a market capitalization of $682.75 million, a PE ratio of -29.76 and a beta of 1.18. The company has a debt-to-equity ratio of 1.46, a current ratio of 7.30 and a quick ratio of 6.45.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The firm had revenue of $9.22 million during the quarter, compared to analysts' expectations of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Sell-side analysts predict that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Hedge Funds Weigh In On ClearPoint Neuro

A number of large investors have recently modified their holdings of the company. Millennium Management LLC raised its holdings in shares of ClearPoint Neuro by 156.3% in the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock worth $8,813,000 after purchasing an additional 452,043 shares during the period. Geode Capital Management LLC raised its holdings in shares of ClearPoint Neuro by 107.3% during the 2nd quarter. Geode Capital Management LLC now owns 624,800 shares of the company's stock valued at $7,461,000 after buying an additional 323,429 shares during the period. Lane Generational LLC raised its holdings in shares of ClearPoint Neuro by 6.8% during the 2nd quarter. Lane Generational LLC now owns 258,427 shares of the company's stock valued at $3,086,000 after buying an additional 16,382 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of ClearPoint Neuro by 98.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock valued at $3,066,000 after buying an additional 127,823 shares during the period. Finally, Conway Capital Management Inc. raised its holdings in shares of ClearPoint Neuro by 31.1% during the 1st quarter. Conway Capital Management Inc. now owns 211,325 shares of the company's stock valued at $2,513,000 after buying an additional 50,100 shares during the period. 30.08% of the stock is currently owned by hedge funds and other institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.